|
Robert Peterson, MD, PhD, MPH
Dr.
Peterson is a pediatrician, clinical pharmacologist, and medical toxicologist
who is a Clinical Professor in the Department of Pediatrics, University of British
Columbia, and Executive Director of the Drug
Safety and Effectiveness Network, Canadian Institutes of Health Research. He is
Chair of the Regulations Advisory Board of the Centre for Medicines Research
International Institute for Regulatory Science. In this capacity, he
participates actively in international drug development and regulation review
and discussion. He was Director General of the Therapeutic Products Directorate
at Health Canada
for five years and led many innovations in drug regulatory policy during that
time. Dr. Peterson has experience in clinical trials, been director of a
research institute, and has participated in numerous international workshops on
drug development. He completed a Master of Public Health degree in the area of
Health Policy and Health Care Management and has a good appreciation of the
evaluation and use of human prescription drugs. Dr. Peterson has been a member
of CEDAC since 2005.
Conflict of Interest Disclosure
Anne Holbrook, MD, PharmD, MSc, FRCPC
Dr.
Holbrook is a clinical pharmacologist and internal medicine specialist with
expertise in pharmacoepidemiology, clinical trials,
and drug policy. She is a Professor and Director, Division of Clinical
Pharmacology & Therapeutics, in the Department of Medicine at McMaster
University, a Senior Scientist at the Centre for Evaluation of Medicines, and an active medical staff member at both St.
Joseph's Healthcare Hamilton and Hamilton
Health Sciences. Dr. Holbrook has broad experience and expertise in
evidence-based therapeutics research, education, and practice and is frequently asked to manage patients with the most
complicated medical histories and drug therapy regimens. She has chaired
and held appointments with numerous federal, provincial, and regional
committees, including serving as Chair of the federal Expert Advisory Committee
on Pharmacovigilance. Dr. Holbrook has been a member of Ontario's Committee
to Evaluate Drugs (formerly the Drug Quality and Therapeutics Committee) since 1997
and has participated on and chaired subcommittees on a variety of drug topics.
Conflict of Interest Disclosure
Members
G. Michael Allan, MD, CCFP
Dr.
Allan is an Associate Professor and Director of Evidence-Based Medicine in the
Department of Family Medicine at the University of Alberta. He coordinates and
teaches the evidence-based medicine curriculum in the family medicine residency
program and the community health course. He is the Medical Director of the
Toward Optimized Practice Program, which works to expand the depth and spread
of evidence-based practice and quality of primary care in Alberta. In addition, Dr. Allan teaches at
conferences, does research in Health Care Economics and Physician Education,
and practises family medicine in a multi-disciplinary team setting. He also
co-presents a weekly evidence-based educational podcast with the Therapeutics Education
Collaboration.
Conflict of Interest Disclosure
Ken Bassett, MD, PhD
Dr.
Ken Bassett is a professor in the departments of Family Practice, Pharmacology
and Therapeutics, Health Care and Epidemiology, and Ophthalmology as well as an
associate member of the Centre for Health Services and Policy Research at the
University of British Columbia (UBC). Dr. Bassett's research interests are in
the systematic review of drug therapy and drug funding policy. He is highly
experienced and skilled in the critical appraisal of drug therapies and has had
considerable experience with practical issues around public plan formularies.
Dr. Bassett has chaired and held appointments with numerous federal and
provincial or local committees, including serving as Chair of the Drug
Assessment Working Group of the UBC Therapeutics Initiative.
Conflict of Interest Disclosure
Bruce Carleton, BPharm, PharmD
Dr.
Carleton is a Professor of Paediatrics and Pharmaceutical Sciences at the
University of British Columbia (UBC). He is also the Director of the
Pharmaceutical Outcomes Program, Children's and Women's Health Centre of BC,
and Senior Clinician Scientist at the Child and Family Research Institute in Vancouver. Dr. Carleton's
relevant experience in the area of drug policy implementation and evaluation
includes work as a reviewer of clinical and pharmacoeconomic studies of drugs.
He is experienced and skilled in the critical appraisal of drug therapies and
has had considerable experience with practical issues around public plan
formularies. He has served on both provincial and federal committees focused on
drug effectiveness, drug safety, and drug policy development.
Conflict of Interest Disclosure
Douglas (Doug) Coyle, MA, MSc, PhD
Dr.
Coyle is a Professor and the Director of Graduate Studies in the Department of
Epidemiology and Community Medicine at the University of Ottawa. He is also a
Senior Scientist at the Ottawa Hospital Research Institute and a former
Research Fellow at the Centre for Health Economics, University of York,
England. He has been a member of the Ontario Committee to Evaluate Drugs since
2006 and the Ontario Drugs for Rare Diseases Working Group since 2008.
Conflict of Interest Disclosure
John Deven
Mr.
Deven is a retired high school principal from Ontario. His undergraduate and
graduate degrees are in biochemistry, microbiology, and pathology. He has been
involved in many committees as chair or vice-chair, including the
Hamilton-Wentworth Community Policing Committee, the Teachers’ Credit Union
Board of Directors, the Hamilton-Wentworth Lung Association, many
education-related committees, and leadership development programs. Mr. Deven
was awarded the Mayor’s Award for Multiculturalism and Anti-Racism from the
City of Hamilton, the Ontario Teachers’ Excellence in Education Award, and the
Royal Canadian Legion’s Community Involvement Award.
Conflict of Interest Disclosure
Alan Forster , MD, FRCPC, MSc
Dr.
Forster is a general internist and Scientific Director of Clinical, Quality,
and Performance Management at the Ottawa
Hospital. In these capacities,
he leads in the development of innovative solutions to address health care
quality problems. He
is an Associate Professor of Medicine at the University of Ottawa and Scientist
in the Clinical Epidemiology Program at the Ottawa Health Research Institute,
where his research focuses on patient safety and quality improvement. He has
been the recipient of several prestigious awards recognizing his work within
the field of health services research. He has performed seminal work evaluating
the incidence of adverse events following discharge from hospital. This work
has lead to the development of strategies to improve care during the transition
home from hospital. He is also leading in the development of a hospital data
warehouse, which will serve as a supporting infrastructure for a research
program in patient safety and quality of care. In addition to his significant
contributions to a quality and safety program at the Ottawa Hospital,
he provides ongoing scientific advice regarding quality of care to provincial
and national organizations, such as the Ontario Health Quality Council.
Conflict of Interest Disclosure
Laurie Mallery, MD, FRCPC
Dr.
Mallery is the Head of the Division of Geriatric Medicine at Dalhousie
University and the Director of the Centre for Health Care of the Elderly at the
Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. She is a
Geriatrician and internist who is committed to evidence-based decision-making,
with experience in drug evaluation. She was a member of the Nova Scotia
Formulary Management Committee since 1993 and served as Chair since 2000. She chaired
the Atlantic Common Drug Review Expert Advisory Committee since it was
established in 2002 until 2009.
Conflict of Interest Disclosure
Brad Neubauer
Mr.
Neubauer, a rancher and businessman in Irvine, Alberta, holds a Bachelor of
Arts degree in Political Science and Philosophy. He has been actively involved
as a member of the public in health care and has served as a member of local
and provincial bioethics and research ethics committees. Mr. Neubauer has also
volunteered his time and efforts in support of the local theatre community in
Medicine Hat.
Conflict of Interest Disclosure
Lindsay Nicolle, MD, FRCPC
Dr.
Nicolle is Professor of Internal Medicine and Medical Microbiology at the
University of Manitoba and Consultant in Adult Infectious Diseases at the
Health Sciences Centre and Winnipeg Regional Health Authority. She was Chair of
the Department of Internal Medicine at the University of Manitoba
from 1996 to 2001 where she has also previously served as a member and Chair of
the Antimicrobial Review and Pharmacy and Therapeutics committees. During a
sabbatical at the World Health Organization in 2001, Dr. Nicolle participated
in the development of the Global Strategy for Antimicrobial Resistance.
Conflict of Interest Disclosure
Yvonne Shevchuk , B.S.P., Pharm D
Dr.
Shevchuk is a Professor in the College of Pharmacy and Nutrition at the
University of Saskatchewan where her areas of teaching focus in infectious
diseases and research methods/evidence-based pharmacotherapy and drug
information. Dr. Shevchuk is a long-time member of the Infectious Diseases
Service at the Royal University Hospital and is involved in direct patient
care. She has extensive committee experience, serving on both the Saskatchewan
Formulary Committee and the Drug Quality Assessment Committee since 1991 and on
the newly formed Drug Advisory Committee of Saskatchewan (DACS) since January
2010. In addition, Dr. Shevchuk is on the Board of the Saskatchewan Health
Quality Council and the Advisory Board of RxFiles and is Director of the
Saskatchewan Drug Information Service.
Conflict of Interest Disclosure
|
